106 related articles for article (PubMed ID: 29398912)
1. The annual direct costs of stable COPD in Greece.
Stafyla E; Geitona M; Kerenidi T; Economou A; Daniil Z; Gourgoulianis KI
Int J Chron Obstruct Pulmon Dis; 2018; 13():309-315. PubMed ID: 29398912
[TBL] [Abstract][Full Text] [Related]
2. The pharmacological cost of COPD during Greek economic crisis.
Stafyla E; Kerenidi T; Gerogianni I; Geitona M; Daniil Z; Gourgoulianis KI
Int J Chron Obstruct Pulmon Dis; 2017; 12():461-466. PubMed ID: 28203069
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of COPD in a Swedish cohort: the ARCTIC study.
Lisspers K; Larsson K; Johansson G; Janson C; Costa-Scharplatz M; Gruenberger JB; Uhde M; Jorgensen L; Gutzwiller FS; Ställberg B
Int J Chron Obstruct Pulmon Dis; 2018; 13():275-285. PubMed ID: 29391785
[TBL] [Abstract][Full Text] [Related]
4. Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009.
Dalal AA; Liu F; Riedel AA
Int J Chron Obstruct Pulmon Dis; 2011; 6():533-42. PubMed ID: 22069365
[TBL] [Abstract][Full Text] [Related]
5. The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada.
Maleki-Yazdi MR; Kelly SM; Lam SY; Marin M; Barbeau M; Walker V
Can Respir J; 2012; 19(5):319-24. PubMed ID: 23061077
[TBL] [Abstract][Full Text] [Related]
6. Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review.
Iheanacho I; Zhang S; King D; Rizzo M; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2020; 15():439-460. PubMed ID: 32161455
[TBL] [Abstract][Full Text] [Related]
7. What is the impact of GOLD 2017 recommendations in primary care? - a descriptive study of patient classifications, treatment burden and costs.
Gayle A; Dickinson S; Morris K; Poole C; Mathioudakis AG; Vestbo J
Int J Chron Obstruct Pulmon Dis; 2018; 13():3485-3492. PubMed ID: 30498338
[TBL] [Abstract][Full Text] [Related]
8. Value of systematic intervention for chronic obstructive pulmonary disease in a regional Japanese city based on case detection rate and medical cost.
Tawara Y; Senjyu H; Tanaka K; Tanaka T; Asai M; Kozu R; Tabusadani M; Honda S; Sawai T
Int J Chron Obstruct Pulmon Dis; 2015; 10():1531-42. PubMed ID: 26347397
[TBL] [Abstract][Full Text] [Related]
9. Clinical factors and comorbidities affecting the cost of hospital-treated COPD.
Deniz S; Şengül A; Aydemir Y; Çeldir Emre J; Özhan MH
Int J Chron Obstruct Pulmon Dis; 2016; 11():3023-3030. PubMed ID: 27980399
[TBL] [Abstract][Full Text] [Related]
10. Social economic costs of COPD in Extremadura (Spain): an observational study.
Merino M; Villoro R; Hidalgo-Vega Á; Carmona C
Int J Chron Obstruct Pulmon Dis; 2018; 13():2501-2514. PubMed ID: 30174420
[TBL] [Abstract][Full Text] [Related]
11. Direct Medical Costs of COPD in the USA: An Analysis of the Medical Expenditure Panel Survey 2017-2018.
Shah CH; Reed RM; Wastila L; Onukwugha E; Gopalakrishnan M; Zafari Z
Appl Health Econ Health Policy; 2023 Nov; 21(6):915-924. PubMed ID: 37270431
[TBL] [Abstract][Full Text] [Related]
12. Determinants of elevated healthcare utilization in patients with COPD.
Simon-Tuval T; Scharf SM; Maimon N; Bernhard-Scharf BJ; Reuveni H; Tarasiuk A
Respir Res; 2011 Jan; 12(1):7. PubMed ID: 21232087
[TBL] [Abstract][Full Text] [Related]
13. The social cost of chronic kidney disease in Italy.
Turchetti G; Bellelli S; Amato M; Bianchi S; Conti P; Cupisti A; Panichi V; Rosati A; Pizzarelli F;
Eur J Health Econ; 2017 Sep; 18(7):847-858. PubMed ID: 27699568
[TBL] [Abstract][Full Text] [Related]
14. Present and future costs of COPD in Iceland and Norway: results from the BOLD study.
Nielsen R; Johannessen A; Benediktsdottir B; Gislason T; Buist AS; Gulsvik A; Sullivan SD; Lee TA
Eur Respir J; 2009 Oct; 34(4):850-7. PubMed ID: 19357148
[TBL] [Abstract][Full Text] [Related]
15. Costs of illness analysis in Italian patients with chronic obstructive pulmonary disease (COPD): an update.
Dal Negro RW; Bonadiman L; Turco P; Tognella S; Iannazzo S
Clinicoecon Outcomes Res; 2015; 7():153-9. PubMed ID: 25834458
[TBL] [Abstract][Full Text] [Related]
16. Annual costs of chronic obstructive pulmonary disease in Finland during 1996-2006 and a prediction model for 2007-2030.
Herse F; Kiljander T; Lehtimäki L
NPJ Prim Care Respir Med; 2015 Mar; 25():15015. PubMed ID: 25811648
[TBL] [Abstract][Full Text] [Related]
17. COPD: The Annual Cost-Of-Illness during the Last Two Decades in Italy, and Its Mortality Predictivity Power.
Dal Negro RW
Healthcare (Basel); 2019 Mar; 7(1):. PubMed ID: 30832210
[TBL] [Abstract][Full Text] [Related]
18. Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review.
Gutiérrez Villegas C; Paz-Zulueta M; Herrero-Montes M; Parás-Bravo P; Madrazo Pérez M
Health Econ Rev; 2021 Aug; 11(1):31. PubMed ID: 34403023
[TBL] [Abstract][Full Text] [Related]
19. Direct and Indirect Costs of Asthma Management in Greece: An Expert Panel Approach.
Souliotis K; Kousoulakou H; Hillas G; Bakakos P; Toumbis M; Loukides S; Vassilakopoulos T
Front Public Health; 2017; 5():67. PubMed ID: 28424767
[TBL] [Abstract][Full Text] [Related]
20. Acute COPD exacerbations and in-hospital treatment-related problems: An observational study.
Awwad O; Abu Farha R; Altaharwah A; Sharaya S; Naser AY; Tabaza H
PLoS One; 2024; 19(6):e0305011. PubMed ID: 38843229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
